跳至主要内容
临床试验/CTRI/2008/091/000229
CTRI/2008/091/000229未知2/3 期

A Randomized, Double-Blind, Placebo-Controlled Study of Donepezil on Cognitive Function and Behaviour in Children with Fragile X Syndrome

Dr Jitendra Kumar Sahu1 个研究点 分布在 1 个国家目标入组 0 人开始时间: 待定

试验速览

阶段
2/3 期
发起方
试验地点
1
主要终点
Intelligence Quotient by Kulshreshta adaptation of the Stanford - Binet Test

研究概览

简要总结

The study is a randomized, double blind, parallel group trial evaluating effect of Donepezil on cognitive function and behavior over 12 weeks period. The primary outcome measure will be change in Stanford-Binet intelligence scale from baseline to 12 weeks.

研究设计

分配方式
Computer generated randomization
盲法
Participant, Investigator, Outcome Assessor and Date-entry Operator Blinded

入排标准

入选标准

  • 1.Confirmed genetic diagnosis of fragile X syndrome by PCR & Southern blot;
  • Age 6-15 yrs; 3.Regardless of their IQ level if they were able to complete the required neuropsychological testing.

排除标准

  • 1.Children below 6 years and beyond 15 years of age;
  • Currently taking any anticholinergic medications or known hypersensitivity to anticholinergic drugs;3.Seizure disorder requiring the use of anticonvulsant medications;4.Clinically significant uncontrolled cardiovascular, renal, hepatic, pulmonary, gastrointestinal, endocrine, metabolic or hematologic conditions.

结局指标

主要结局

Intelligence Quotient by Kulshreshta adaptation of the Stanford - Binet Test

时间窗: Baseline & 12 week

次要结局

  • Childhood Autism Rating Scale(Baseline, 12 Week)

研究者

发起方
Dr Jitendra Kumar Sahu

研究点 (1)

Loading locations...

相似试验